Levodopa-induced dyskinesias represent a major shortcoming of Parkinson's disease management, and its pharmacological treatment is generally unsatisfactory. However, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias.